M&A Deal Summary

Arbutus Biopharma Acquires OnCore Biopharma

On March 4, 2015, Arbutus Biopharma acquired life science company OnCore Biopharma

Acquisition Highlights
  • This is Arbutus Biopharma’s 1st transaction in the Life Science sector.
  • This is Arbutus Biopharma’s 1st transaction in the United States.
  • This is Arbutus Biopharma’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2015-03-04
Target OnCore Biopharma
Sector Life Science
Buyer(s) Arbutus Biopharma
Deal Type Merger

Target

OnCore Biopharma

Doylestown, Pennsylvania, United States
OnCore Biopharma, Inc. is a biopharmaceutical company provides research, development, and commercialization of therapies.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arbutus Biopharma

Warminster, Pennsylvania, United States
Category Company
Sector Life Science
Employees73
Revenue 18M USD (2023)
DESCRIPTION

Arbutus Biopharma is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). Arbutus Biopharma is based in Warminster, Pennsylvania.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-05-30 Protiva Biotherapeutics

Burnaby, British Columbia, Canada

Protiva Biotherapeutics, Inc. is a biotechnology company, develops nucleic acid based pharmaceutical products.

Buy -
Mergr

Product

Company

Legal